Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects With Acromegaly Treated With Long-acting Somatostatin Receptor Ligands (PATHFNDR-1)

Next Previous
Trial Profile

A Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects With Acromegaly Treated With Long-acting Somatostatin Receptor Ligands (PATHFNDR-1)

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 15 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paltusotine (Primary)
  • Indications Acromegaly
  • Focus Registrational; Therapeutic Use
  • Acronyms PATHFNDR-1
  • Sponsors Crinetics Pharmaceuticals

Most Recent Events

  • 30 Jun 2025 According to a Crinetics Pharmaceuticals media release, company will present data from PATHFNDR-2 and PATHFNDR-1 studies at the Endocrine Society's Annual Meeting, ENDO 2025, July 12-15, 2025, in San Francisco, California.
  • 15 May 2025 According to a Crinetics Pharmaceuticals media release, company will present post hoc data from PATHFNDR-1, PATHFNDR-2, and ACROBAT Advance studies at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2025, taking place May 15-17 in Orlando, FL.
  • 28 Mar 2025 According to a Crinetics Pharmaceuticals media release, company announced that European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for paltusotine on the basis of PATHFNDR-1 and PATHFNDR-2 studies and data from 18 clinical trials.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top